search
Back to results

Long Term Safety and Efficacy of Butterfly Medical Prostatic Retraction Device in Benign Prostatic Hyperplasia (BPH) Patients Who Completed 12 Months of Follow-Up Post Implantation (Continuation Study for Study BM-011-IL)

Primary Purpose

BPH, BOO - Bladder Outflow Obstruction, Enlarged Prostate (BPH)

Status
Recruiting
Phase
Not Applicable
Locations
Israel
Study Type
Interventional
Intervention
Butterfly Medical Prostatic Retraction Device ("the Butterfly device") removal/replacement
Sponsored by
Butterfly Medical Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for BPH focused on measuring LUTS, Urinary obstruction, Retrograde ejaculation

Eligibility Criteria

50 Years - 80 Years (Adult, Older Adult)MaleDoes not accept healthy volunteers

Inclusion Criteria:

  1. Completed 12 months follow up under study BM-011-IL. A subject that missed one or more visits during BM-011-IL will be included, as long as the subject has collected data at 12 months follow up visit.
  2. Provide signed informed consent to the continuation study and be willing and able to perform follow up visits and activities as described in the study protocol.

Exclusion Criteria:

1. Patients which participated in the BM-011-IL study and did not complete 12 months follow up visit under study BM-011-IL due to any reason

Sites / Locations

  • Rabin Medical CenterRecruiting
  • Ziv Medical CenterRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Patients Who Completed 12 Months of Follow-Up Post Butterfly Implantation

Arm Description

Continuation study for Study BM-011-IL

Outcomes

Primary Outcome Measures

Incidence of Serious adverse events (SAEs) and adverse events (AEs) related to the Butterfly Device.
Serious adverse events (SAEs) and adverse events (AEs) related to treatment with the Butterfly Device.
Change in IPSS change in post implantation patients.
Evaluate the change in IPSS during the FU at each timepoints in comparison to baseline before treatment.

Secondary Outcome Measures

Incidence of device extraction and re-treatment
Rate and Time to device removal and re treatment
Rate of sexual dysfunction
Retrograde ejaculation rate in comparison to rate before treatment

Full Information

First Posted
March 28, 2022
Last Updated
August 6, 2023
Sponsor
Butterfly Medical Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT05330520
Brief Title
Long Term Safety and Efficacy of Butterfly Medical Prostatic Retraction Device in Benign Prostatic Hyperplasia (BPH) Patients Who Completed 12 Months of Follow-Up Post Implantation (Continuation Study for Study BM-011-IL)
Official Title
Prospective, Open-Label, Non-Comparative, Study to Assess the Long Term Safety and Efficacy of Butterfly Medical Prostatic Retraction Device in Benign Prostatic Hyperplasia (BPH) Patients Who Completed 12 Months of Follow-Up Post Implantation (Continuation Study for Study BM-011-IL)
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
February 10, 2021 (Actual)
Primary Completion Date
February 1, 2027 (Anticipated)
Study Completion Date
February 1, 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Butterfly Medical Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study evaluates the long term safety and efficacy of use of the Butterfly Medical's prostatic retraction device in Benign Prostatic Hyperplasia (BPH) Patients. The study follows patients implanted with the Butterfly device for up to 5 year after implantation. The evaluations include recording of safety events and BPH related symptoms by Uroflowmetry tests, residual urine and International Prostate Symptom Score (IPSS) questionnaires. The study also assesses the sexual quality of life after implantation of the Butterfly device.
Detailed Description
Benign prostatic hyperplasia (BPH) is a noncancerous enlargement of the prostate gland that may restrict the flow of urine from the bladder. BPH is a proliferative process of the cellular elements of the prostate, also referred as enlarged prostate. Cellular accumulation and gland enlargement may be due to epithelial and stromal proliferation, impaired pre-programmed cell death (apoptosis), or both. More recently, the voiding dysfunction that ensues from prostate gland enlargement and bladder outlet obstruction (BOO) has been generically termed lower urinary tract symptoms (LUTS). These entities overlap; not all men with BPH have LUTS, and, likewise, not all men with LUTS have BPH. The same can be said for BOO. An estimated 50% of men demonstrate histopathologic BPH by age 60 years. This number increases to 90% by age 85 years; thus, increasing gland size is considered a normal part of the aging process (2-5). Approximately half of those diagnosed with histopathologic BPH demonstrate moderate-to-severe LUTS. Clinical manifestations of LUTS include urinary frequency, urgency, nocturia (getting up at night during sleep to urinate), decreased or intermittent force of stream, or a sensation of incomplete emptying. Complications occur less commonly but may include acute urinary retention, impaired bladder emptying, or the need for surgery. The Butterfly Medical Prostatic Retraction Device is a retraction device, specially designed to be delivered into the prostatic urethra and indicated to dilate the prostatic urethra in BPH patients. This device was specially designed to reduce most of the known complications of used urethral stents. The current clinical study is aimed to investigate the long term technical performance and clinical usage of Butterfly Medical Prostatic Retraction Device, through a 4 year follow up period, as a continuation of study BM-011-IL which assessed the above for a duration of 12 month post implantation.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
BPH, BOO - Bladder Outflow Obstruction, Enlarged Prostate (BPH)
Keywords
LUTS, Urinary obstruction, Retrograde ejaculation

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Patients Who Completed 12 Months of Follow-Up Post Butterfly Implantation
Arm Type
Experimental
Arm Description
Continuation study for Study BM-011-IL
Intervention Type
Procedure
Intervention Name(s)
Butterfly Medical Prostatic Retraction Device ("the Butterfly device") removal/replacement
Intervention Description
when necessary, the device may be removed or replaced easily through the urethra due to its minimal surface and easy release from the mucosa covering it.
Primary Outcome Measure Information:
Title
Incidence of Serious adverse events (SAEs) and adverse events (AEs) related to the Butterfly Device.
Description
Serious adverse events (SAEs) and adverse events (AEs) related to treatment with the Butterfly Device.
Time Frame
60 month post procedure
Title
Change in IPSS change in post implantation patients.
Description
Evaluate the change in IPSS during the FU at each timepoints in comparison to baseline before treatment.
Time Frame
60 month post procedure
Secondary Outcome Measure Information:
Title
Incidence of device extraction and re-treatment
Description
Rate and Time to device removal and re treatment
Time Frame
60 month post procedure
Title
Rate of sexual dysfunction
Description
Retrograde ejaculation rate in comparison to rate before treatment
Time Frame
60 month post procedure

10. Eligibility

Sex
Male
Gender Based
Yes
Minimum Age & Unit of Time
50 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Completed 12 months follow up under study BM-011-IL. A subject that missed one or more visits during BM-011-IL will be included, as long as the subject has collected data at 12 months follow up visit. Provide signed informed consent to the continuation study and be willing and able to perform follow up visits and activities as described in the study protocol. Exclusion Criteria: 1. Patients which participated in the BM-011-IL study and did not complete 12 months follow up visit under study BM-011-IL due to any reason
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Vardit Segal, Ph.D
Phone
+972524579178
Email
vardit@butterfly-medical.com
First Name & Middle Initial & Last Name or Official Title & Degree
Idan Geva
Phone
+972504043838
Email
Idan.geva@butterfly-medical.com
Facility Information:
Facility Name
Rabin Medical Center
City
Petah tikva
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shachar Aharoni, Dr.
Email
shacharA3@clalit.org.il
First Name & Middle Initial & Last Name & Degree
Inbal Grossman
Email
inbalgr3@clalit.org.il
Facility Name
Ziv Medical Center
City
Safed
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ran Katz, Dr.
Email
ran.k@ziv.health.gov.il
First Name & Middle Initial & Last Name & Degree
Yara Safadi
Email
yara.s@ziv.health.gov.il

12. IPD Sharing Statement

Learn more about this trial

Long Term Safety and Efficacy of Butterfly Medical Prostatic Retraction Device in Benign Prostatic Hyperplasia (BPH) Patients Who Completed 12 Months of Follow-Up Post Implantation (Continuation Study for Study BM-011-IL)

We'll reach out to this number within 24 hrs